Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration

Neurobiology of Disease

Volumn 82, Issue , 2015, Pages 185-199

  Paumier, Katrina L ^a,b   Luk, Kelvin C ^c   Manfredsson, Fredric P ^a,b   Kanaan, Nicholas M ^a,b   Lipton, Jack W ^a,b   Collier, Timothy J ^a,b   Steece Collier, Kathy ^a,b   Kemp, Christopher J ^a   Celano, Stephanie ^a   Schulz, Emily ^a   Sandoval, Ivette M ^a   Fleming, Sheila ^d   Dirr, Elliott ^d   Polinski, Nicole K ^a   Trojanowski, John Q ^c   Lee, Virginia M ^c   Sortwell, Caryl E ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Hauenstein Neuroscience Center   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Alpha synuclein; Neurodegeneration; Parkinson's disease; Pre formed fibrils; Propagation; Rats

Indexed keywords

ALPHA SYNUCLEIN; AMPHETAMINE; DOPAMINE; HOMOVANILLIC ACID; PROTEIN P62; PROTEINASE K; RECOMBINANT PROTEIN; THIOFLAVINE; UBIQUITIN;

ADULT; AMYGDALOID NUCLEUS; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INCLUSION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FORELIMB; FRONTAL CORTEX; INNERVATION; INSULA; LEWY BODY; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; SPRAGUE DAWLEY RAT; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA PARS COMPACTA; VOCALIZATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; NERVE DEGENERATION; PATHOLOGY; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; MALE; MICE; MOTOR ACTIVITY; NERVE DEGENERATION; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; VOCALIZATION, ANIMAL;

EID: 84934955012     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.06.003     Document Type: Article

References (59)

1. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2001, 2:492-501.
2. Stefanis L. Alpha-synuclein in Parkinson's disease. Cold Spring Harb. Perspect. Med. 2012, 2:a009399.
3. Kiely A.P., Asi Y.T., Kara E., Limousin P., Ling H., Lewis P., et al. Alpha-synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. Acta Neuropathol. 2013, 125:753-769.
4. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
5. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
6. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
7. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 1998, 4:1318-1320.
8. Yonetani M., Nonaka T., Masuda M., Inukai Y., Oikawa T., Hisanaga S., et al. Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J. Biol. Chem. 2009, 284:7940-7950.
9. Braak E., Sandmann-Keil D., Rub U., Gai W.P., de Vos R.A., Steur E.N., et al. Alpha-synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol. 2001, 101:195-201.
10. Muller C.M., de Vos R.A., Maurage C.A., Thal D.R., Tolnay M., Braak H. Staging of sporadic Parkinson disease-related alpha-synuclein pathology: inter- and intra-rater reliability. J. Neuropathol. Exp. Neurol. 2005, 64:623-628.
11. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
12. Ulusoy A., Rusconi R., Perez-Revuelta B.I., Musgrove R.E., Helwig M., Winzen-Reichert B., et al. Caudo-rostral brain spreading of alpha-synuclein through vagal connections. EMBO Mol. Med. 2013, 5:1051-1059.
13. Bancher C., Braak H., Fischer P., Jellinger K.A. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci. Lett. 1993, 162:179-182.
14. Chu Y., Kordower J.H. Lewy body pathology in fetal grafts. Ann. N. Y. Acad. Sci. 2010, 1184:55-67.
15. Li J.Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
16. Kordower J.H., Dodiya H.B., Kordower A.M., Terpstra B., Paumier K., Madhavan L., et al. Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiol. Dis. 2011, 43:552-557.
17. Hansen C., Angot E., Bergstrom A.L., Steiner J.A., Pieri L., Paul G., et al. Alpha-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 2011, 121:715-725.
18. Volpicelli-Daley L.A., Luk K.C., Patel T.P., Tanik S.A., Riddle D.M., Stieber A., et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011, 72:57-71.
19. Freundt E.C., Maynard N., Clancy E.K., Roy S., Bousset L., Sourigues Y., et al. Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport. Ann. Neurol. 2012, 72:517-524.
20. Holmes B.B., DeVos S.L., Kfoury N., Li M., Jacks R., Yanamandra K., et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E3138-E3147.
21. Luk K.C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J.Q., et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338:949-953.
22. Recasens A., Dehay B., Bove J., Carballo-Carbajal I., Dovero S., Perez-Villalba A., et al. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 2014, 75:351-362.
23. Masuda-Suzukake M., Nonaka T., Hosokawa M., Oikawa T., Arai T., Akiyama H., et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain 2013, 136:1128-1138.
24. Pan-Montojo F., Schwarz M., Winkler C., Arnhold M., O'Sullivan G.A., Pal A., et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci. Rep. 2012, 2:898.
25. Antony P.M., Diederich N.J., Balling R. Parkinson's disease mouse models in translational research. Mamm. Genome 2011, 22:401-419.
26. Koprich J.B., Johnston T.H., Reyes M.G., Sun X., Brotchie J.M. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. Mol. Neurodegener. 2010, 5:43.
27. Gombash S.E., Manfredsson F.P., Kemp C.J., Kuhn N.C., Fleming S.M., Egan A.E., et al. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. PLoS One 2013, 8:e81426.
28. Whishaw I.Q., Metz G.A., Kolb B., Pellis S.M. Accelerated nervous system development contributes to behavioral efficiency in the laboratory mouse: a behavioral review and theoretical proposal. Dev. Psychobiol. 2001, 39:151-170.
29. Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J., Scherer S., et al. Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 2004, 428:493-521.
30. Lin J.H. Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 1995, 23:1008-1021.
31. Volpicelli-Daley L.A., Luk K.C., Lee V.M. Addition of exogenous alpha-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates. Nat. Protoc. 2014, 9:2135-2146.
32. Schallert T. Behavioral tests for preclinical intervention assessment. NeuroRx 2006, 3:497-504.
33. Spieles-Engemann A.L., Behbehani M.M., Collier T.J., Wohlgenant S.L., Steece-Collier K., Paumier K., et al. Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss. Neurobiol. Dis. 2010, 39:105-115.
34. Basken J.N., Connor N.P., Ciucci M.R. Effect of aging on ultrasonic vocalizations and laryngeal sensorimotor neurons in rats. Exp. Brain Res. 2012, 219:351-361.
35. Bialy M., Rydz M., Kaczmarek L. Precontact 50-kHz vocalizations in male rats during acquisition of sexual experience. Behav. Neurosci. 2000, 114:983-990.
36. Ringel L.E., Basken J.N., Grant L.M., Ciucci M.R. Dopamine D1 and D2 receptor antagonism effects on rat ultrasonic vocalizations. Behav. Brain Res. 2013, 252:252-259.
37. Gombash S.E., Manfredsson F.P., Mandel R.J., Collier T.J., Fischer D.L., Kemp C.J., et al. Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways. Gene Ther. 2014, 21:682-693.
38. Kelenyi G. Thioflavin S, fluorescent and Congo red anisotropic stainings in the histologic demonstration of amyloid. Acta Neuropathol. 1967, 7:336-348.
39. Gundersen H.J., Jensen E.B., Kieu K., Nielsen J. The efficiency of systematic sampling in stereology - reconsidered. J. Microsc. 1999, 193:199-211.
40. Koprich J.B., Campbell N.G., Lipton J.W. Neonatal 3,4-methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases brain-derived neurotrophic factor in the forebrain and brainstem of the rat. Brain Res. Dev. Brain Res. 2003, 147:177-182.
41. Koprich J.B., Chen E.Y., Kanaan N.M., Campbell N.G., Kordower J.H., Lipton J.W. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicol. Teratol. 2003, 25:509-517.
42. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 2002, 22:2780-2791.
43. Double K.L., Reyes S., Werry E.L., Halliday G.M. Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions?. Prog. Neurobiol. 2010, 92:316-329.
44. Kanaan N.M., Kordower J.H., Collier T.J. Age-related changes in dopamine transporters and accumulation of 3-nitrotyrosine in rhesus monkey midbrain dopamine neurons: relevance in selective neuronal vulnerability to degeneration. Eur. J. Neurosci. 2008, 27:3205-3215.
45. Wall N.R., De La Parra M., Callaway E.M., Kreitzer A.C. Differential innervation of direct- and indirect-pathway striatal projection neurons. Neuron 2013, 79:347-360.
46. Sacino A.N., Brooks M., McKinney A.B., Thomas M.A., Shaw G., Golde T.E., et al. Brain injection of alpha-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. J. Neurosci. 2014, 34:12368-12378.
47. McNaught K.S., Jnobaptiste R., Jackson T., Jengelley T.A. The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease. Synapse 2010, 64:241-250.
48. Pasquier D.A., Kemper T.L., Forbes W.B., Morgane P.J. Dorsal raphe, substantia nigra and locus coeruleus: interconnections with each other and the neostriatum. Brain Res. Bull. 1977, 2:323-339.
49. Taguchi K., Watanabe Y., Tsujimura A., Tatebe H., Miyata S., Tokuda T., et al. Differential expression of alpha-synuclein in hippocampal neurons. PLoS One 2014, 9:e89327.
50. Breydo L., Wu J.W., Uversky V.N. Alpha-synuclein misfolding and Parkinson's disease. Biochim. Biophys. Acta 1822, 2012:261-285.
51. Marinus J., van Hilten J.J. The significance of motor (A)symmetry in Parkinson's disease. Mov. Disord. 2015, 30:379-385.
52. Nandhagopal R., Kuramoto L., Schulzer M., Mak E., Cragg J., Lee C.S., et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009, 132:2970-2979.
53. Decressac M., Mattsson B., Lundblad M., Weikop P., Bjorklund A. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol. Dis. 2012, 45:939-953.
54. Decressac M., Mattsson B., Bjorklund A. Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease. Exp. Neurol. 2012, 235:306-315.
55. Ciucci M.R., Ahrens A.M., Ma S.T., Kane J.R., Windham E.B., Woodlee M.T., et al. Reduction of dopamine synaptic activity: degradation of 50-kHz ultrasonic vocalization in rats. Behav. Neurosci. 2009, 123:328-336.
56. Ciucci M.R., Ma S.T., Fox C., Kane J.R., Ramig L.O., Schallert T. Qualitative changes in ultrasonic vocalization in rats after unilateral dopamine depletion or haloperidol: a preliminary study. Behav. Brain Res. 2007, 182:284-289.
57. Carneiro D., das Gracas Wanderley de Sales Coriolano M., Belo L.R., de Marcos Rabelo A.R., Asano A.G., Lins O.G. Quality of life related to swallowing in Parkinson's disease. Dysphagia 2014, 29:578-582.
58. Grant L.M., Richter F., Miller J.E., White S.A., Fox C.M., Zhu C., et al. Vocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson's disease. Behav. Neurosci. 2014, 128:110-121.
59. Ciucci M.R., Ma S.T., Kane J.R., Ahrens A.M., Schallert T. Limb use and complex ultrasonic vocalization in a rat model of Parkinson's disease: deficit-targeted training. Parkinsonism Relat. Disord. 2008, 14(Suppl. 2):S172-S175.